The Charles H. Revson Foundation Elects Dr. Stephen Blacklow to Board of Trustees
The Revson Foundation has announced Dr. Stephen Blacklow’s election to the Board of Directors, effective November 1, 2022.
Dr. Blacklow is currently the Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and a member of the Department of Cancer Biology at the Dana Farber Cancer Institute.
Research by Dr. Blacklow’s team has advanced understanding of how signaling between different cells induces growth and changes in cell identity both in normal development and in cancer. He has elucidated key molecular events in Notch signal transduction, showing how cell surface receptors can convey a developmental signal directly from one contacting cell surface to the next and then from the membrane to the nucleus. His research on the Notch pathway has led to the development of new investigational therapies for hematologic malignancies such as T cell acute lymphocytic leukemia (ALL).
Dr. Blacklow was named a Pfizer Scholar in 1997, a Pew Scholar in 1999, and an Established Investigator of the American Heart Association in 2002. He was a recipient of the National Cancer Institute’s prestigious Outstanding Investigator Award in 2017 and was elected to the Association of American Physicians in 2018. Dr. Blacklow directed the MD-PhD Program in Basic and Translational Sciences at Harvard Medical School from 2007-2012 and has served on Advisory Committees for pre-clinical departments, graduate programs, and MD-PhD programs at several major research universities and institutions, including Stanford, the University of Pennsylvania, and the Memorial Sloan Kettering Cancer Center.
Dr. Blacklow received his MD and PhD degrees from Harvard University in 1991, completed his residency in Clinical Pathology at Brigham and Women’s Hospital, and carried out postdoctoral research at the Whitehead Institute with Dr. Peter S. Kim.